ID 566 - Kwas dokozaheksaenowy, Kwas eikozapentaenowy

PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy
EN: DHA+EPA - long chain omega 3 fatty acids
Pdf: eicosapentaenoic acid

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent which is the subject of the health claims is mixed long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFA), namely docosahexaenoic acid (DHA) in combination with eicosapentaenoic acid (EPA) and, for ID 703, with docosapentaenoic acid (DPA).
The n-3 LCPUFA EPA, DHA and DPA are recognised nutrients and are measurable in foods by established methods. They are well absorbed when consumed in the form of triglycerides. This evaluation applies to EPA, DHA and, for ID 703, DPA from all sources with suitable bioavailability in the specified amounts.
The Panel considers that the food constituent, EPA, DHA and DPA, which is the subject of the health claims, is sufficiently characterised.

2.2. Utrzymanie prawidłowego stężenia glukozy we krwi (ID 566)

The claimed effect is “carbohydrate metabolism and insulin sensitivity”. The Panel assumes that the target population is the general population.
In the context of the proposed wording, the Panel assumes that the claimed effect refers to the long- term maintenance or achievement of normal blood glucose concentrations.
The Panel considers that long-term maintenance of normal blood glucose concentrations is a beneficial physiological effect.

3.2. Utrzymanie prawidłowego stężenia glukozy we krwi (ID 566)

Three references were provided for the scientific substantiation of this claim. One was a narrative review on n-3 fatty acids and the metabolic syndrome, one reported on an intervention study on the effects of a hypocaloric low-fat dietary intervention limiting intake of fatty fish and fish oil supplements on membrane fatty acid composition and insulin sensitivity, and the third reference reported on an intervention study investigating the acute effects of n-3 long-chain polyunsaturated fatty acids on dexamethasone-induced insulin resistance in healthy human volunteers. No measures of blood glucose control were reported in any of these studies. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claimed effect.
The Panel concludes that a cause and effect relationship has not been established between the consumption of EPA and DHA and long-term maintenance of normal blood glucose concentrations.

Warunki i możliwe ograniczenia stosowania oświadczenia

Food supplement with 590 mg of eicosapentaenoic acid (EPA) and 83 mg of docosahexaenoic acid (DHA) in the daily dose.